Get the Stockscreener App
2.49
5.96%
0.14
Alzamend Neuro Inc stock is traded at $2.49, with a volume of 113.47K.
It is up +5.96% in the last 24 hours and down -22.19% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$2.35
Open:
$2.31
24h Volume:
113.47K
Relative Volume:
0.08
Market Cap:
$7.21M
Revenue:
-
Net Income/Loss:
$-5.85M
P/E Ratio:
-0.3723
EPS:
-6.6877
Net Cash Flow:
$-8.00M
1W Performance:
+4.84%
1M Performance:
-22.19%
6M Performance:
-71.11%
1Y Performance:
-91.84%
1-Day Range:
$2.31
$2.54
1-Week Range:
$2.25
$2.54
52-Week Range:
$2.06
$31.40
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
3500 LENOX RD. NE, ATLANTA
Compare ALZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
2.49 | 7.47M | 0 | -5.85M | -8.00M | -6.6877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
Relative strength of Alzamend Neuro Inc. in sector analysisJuly 2025 Action & Momentum Based Trading Ideas - Newser
What machine learning models say about Alzamend Neuro Inc.2025 Market Outlook & Verified Momentum Stock Alerts - Newser
How to use Fibonacci retracement on Alzamend Neuro Inc.Quarterly Risk Review & Weekly Stock Breakout Alerts - Newser
Will Alzamend Neuro Inc. continue its uptrendAnalyst Downgrade & Daily Volume Surge Signals - Newser
What technical models suggest about Alzamend Neuro Inc.’s comebackQuarterly Profit Review & Risk Adjusted Buy and Sell Alerts - Newser
Visualizing Alzamend Neuro Inc. stock with heatmapsJuly 2025 Review & Weekly High Potential Alerts - Newser
Alzamend Neuro Inc. stock momentum explainedJuly 2025 Sentiment & Detailed Earnings Play Strategies - Newser
Will Alzamend Neuro Inc. outperform the marketWeekly Stock Recap & Scalable Portfolio Growth Ideas - Newser
Can Alzamend Neuro Inc. hit a new high this monthJuly 2025 Trade Ideas & Smart Swing Trading Techniques - Newser
Will Alzamend Neuro Inc. stock recover after recent dropJuly 2025 Movers & Daily Volume Surge Signals - Newser
Applying Elliott Wave Theory to Alzamend Neuro Inc.Earnings Overview Report & Consistent Return Strategy Ideas - Newser
Alzamend Neuro Inc. Hits Oversold Level on RSI IndicatorWeekly Earnings Recap & Real-Time Buy Zone Alerts - newsimpact.co.kr
Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Expands By 79.6% - Defense World
Published on: 2025-08-18 01:33:08 - Newser
Signal strength of Alzamend Neuro Inc. stock in tech scannersJuly 2025 Movers & Smart Swing Trading Techniques - Newser
Will Alzamend Neuro Inc. rebound enough to break evenGap Down & Advanced Swing Trade Entry Alerts - Newser
Published on: 2025-08-17 18:25:55 - Newser
Can technical indicators confirm Alzamend Neuro Inc.’s reversalJuly 2025 Decliners & Weekly Breakout Watchlists - Newser
What MACD and RSI say about Alzamend Neuro Inc.Earnings Recap Summary & Weekly High Return Stock Opportunities - Newser
Key resistance and support levels for Alzamend Neuro Inc.CEO Change & Low Risk High Win Rate Stock Picks - Newser
Regression analysis insights on Alzamend Neuro Inc. performanceJuly 2025 Decliners & Accurate Technical Buy Alerts - Newser
How to recover losses in Alzamend Neuro Inc. stock2025 Market Trends & Scalable Portfolio Growth Methods - Newser
Forecasting Alzamend Neuro Inc. price range with options dataQuarterly Profit Summary & AI Enhanced Trading Signals - Newser
Drawdown in Alzamend Neuro Inc. May Be Nearing EndJuly 2025 Outlook & Community Consensus Stock Picks - newsyoung.net
Alzamend Neuro Inc. Nearing Breakout Level After BounceMarket Performance Recap & Smart Investment Allocation Tips - beatles.ru
Published on: 2025-08-14 03:56:45 - Newser
How Alzamend Neuro Inc. stock performs during market volatilityProduct Launch & High Win Rate Trade Alerts - Newser
Tools to monitor Alzamend Neuro Inc. recovery probability2025 Market Overview & AI Enhanced Execution Alerts - Newser
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alzamend Neuro Inc Stock (ALZN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
Jul 30 '25 |
Sale |
2.51 |
29,449 |
73,982 |
108,260 |
| AULT MILTON C III | Director |
Jul 25 '25 |
Sale |
2.90 |
36,532 |
105,855 |
46,020 |
| AULT MILTON C III | Director |
Jul 28 '25 |
Sale |
2.68 |
8,311 |
22,314 |
37,709 |
| AULT MILTON C III | Director |
Jul 23 '25 |
Sale |
2.95 |
59,516 |
175,584 |
92,173 |
| AULT MILTON C III | Director |
Jul 24 '25 |
Sale |
2.93 |
9,621 |
28,237 |
82,552 |
| AULT MILTON C III | Director |
May 12 '25 |
Sale |
5.06 |
1,213 |
6,138 |
8,260 |
| AULT MILTON C III | Director |
May 12 '25 |
Sale |
5.28 |
11 |
58 |
1,843 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):